Celia has more than 20 years’ experience in venture capital. She is a co-founder of Supernova Invest and is responsible for the early-stage investment team, the healthcare sector as well as the Supernova 2 and Supernova Innovation 3 funds.
Before joining Supernova Invest, Celia held several positions at Cambridge Antibody Technology (Medimmune since its acquisition by AstraZeneca), one of the stars of UK biotech.
She played a role in developing a number of therapeutic antibodies, including some in co-development with international industrial partners.
Celia is a member of the board of directors or supervisory board of several companies, including Cairdac, Carthera, Diabeloop, Keranova, NH Theraguix, Uromems, Acusurgical and Allotex.
Celia holds a master’s degree in chemistry from the University of Geneva (Switzerland), a PhD from the University of Oxford, and an MBA from Grenoble École de Management (France).